The MYTHIC trial showed activity for lunresertib plus zedoresertib in platinum-resistant ovarian cancer, with dosing at the potential recommended phase 2 dose reaching a 50% overall response rate and 80% of patients reporting tumor shrinkage, according to data shared at a medical meeting. The regimen also showed higher response in the CCNE1-amplified subgroup, where ORR rose to 60% at RP2D. The FDA granted fast track designation for the combination in adults with CCNE1-amplified (or FBXW7/PPP2R1A-deleterious) platinum-resistant/refractory ovarian cancer. The update matters for the ovarian cancer pipeline because it ties biomarker-enriched responses to an expedited regulatory pathway, potentially narrowing the route to confirmatory studies.